Abstract
A reliable, accurate noninvasive method for identifying patients with gastroesophageal reflux disease (GERD) in the primary care setting is needed. A population-based case-finding instrument may assist managed care organizations in identifying candidates for disease management or quality improvement programs. Our aim was to develop and validate a GERD case-finding instrument. A 12-item “GERD Screener” was developed based on literature review and expert opinion with questions about heartburn and regurgitation frequency and severity and medication use, as well demographics and exclusion criteria. Categorical and continuous scoring methods with and without medication use were developed a priori. Using a telephone interview in a medical group, we identified and enrolled 100 subjects with a history of GERD-like symptoms and 103 controls. Each subject completed the GERD Screener, a validated gastrointestinal symptom questionnaire, the Digestive Health Symptom Index (DHSI), and was evaluated independently by two gastroenterologists using a structured format. Agreement by the two physicians that symptoms were consistent with GERD and required an intervention was considered the gold standard. In all, 70 subjects were classified as having GERD and 106 as controls using the gold standard (κ = 0.73; 95% CI, 0.63–0.82). The scoring method for the screening instrument using a continuous measure of GERD symptoms (frequency and severity) and weighted medication use resulted in an area under ROC of 0.89 (95% CI, 0.84–0.94). Using a cutoff of >9 points, this measure was 83% sensitive and 83% specific. Compared to the gold standard, the DHSI GERD subscale has an area under ROC of 0.89 (95% CI, 0.84–0.94). The GERD Screener was highly correlated with the DHSI GERD subscale, r = 0.78 (95% CI 0.72–0.83; P < 0.0001). In conclusion, the GERD Screener has demonstrated construct, convergent, and predictive validity. It is shorter than existing validated instruments, practical, and easily administered, which may reduce the response and administrative burden. This may serve as a valuable case-finding instrument in primary-care and managed-care organizations wishing to implement programs to improve the quality and efficiency of care.
Similar content being viewed by others
REFERENCES
Gallup: A Gallup Organization national survey: Heartburn across America. The Gallup Organization Inc., Princeton, NJ, 1988
Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology 112:1448–1456, 1997
Nebel OT, Fornes MF, Castell DO: Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am J Dig Dis 21:953–956, 1976
Trimble KC, Douglas S, Pryde A, Heading RC: Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 40:1098–1104, 1995
Galmiche JP, Bruley des Varannes S: Symptoms and disease severity in gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 201:62–68, 1994
Eggleston A, Wigerinck A, Huijghebaert S, Dubois D, Haycox A: Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: A clinical database analysis. Gut 42:13–6, 1998
Segal R, Russell WL, Ben-Joseph R, Mansheim B: Cost of acid peptic disorders in a managed-care organization. Clin Ther 18:319–333, 1996
Keyser MS, Crawley JA, Goldberg GA, Shaw MM: Gastroesophageal reflux disease in a managed care setting: Professional, facility, and pharmacy charges. J Managed Care Pharm 4:64–70, 1998
Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274:474–477, 1995
Lagergren J, Bergstrom R, Lindgren A, Nyren O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma [see comments]. N Engl J Med 340:825–831, 1999
Corder AP, Jones RH, Sadler GH, Daniels P, Johnson CD: Heartburn, oesophagitis and Barrett's oesophagus in selfmedicating patients in general practice. Br J Clin Pract 50:245–248, 1996
Simon TJ, Berln RG, Gardner AH, Stauffer LA, Gould AL, Getson AJ: Self-directed treatment of heartburn: A randomized, multicenter, double-blind, placebo-controlled evaluation of antacid and low doses of an H2-receptor antagonist (famotidine). Am J Thera 2:304–313, 1995
Dimenas E: Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 199:18–21, 1993
Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S: Evidence-based disease management. JAMA 278:1687–1692, 1997
Denton M, Borenstein J, Deutsch S: The role of clinical practice guidelines in implementing a disease state management program in hypertension. New Med 1:123–128, 1997
Isolauri J, Laippala P: Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med 27:67–70, 1995
Johnsson F, Joelsson B, Gudmundsson K, Greiff L: Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 22:714–718, 1987
Locke GR, Talley NJ, Weaver AL, Zinsmeister AR: A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 69:539–547, 1994
Shaw M, Talley NJ, Adlis S, Beebe T, Tomshine P, Healey M: Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. Aliment Pharmacol Ther 12:1067–78, 1998
Arthur A, Jagger C, Lindesay J, Graham C, Clarke M: Using an annual over-75 health check to screen for depression: Validation of the short Geriatric Depression Scale (GDS15) within general practice. Int J Geriatr Psychiatry 14:431–439, 1999
Weyerer S, Killmann U, Ames D, Allen N: The Even Briefer Assessment Scale for Depression (EBAS DEP): Its suitability for the elderly in geriatric care in English-and Germanspeaking countries. Int J Geriatr Psychiatry 14:473–480, 1999
Lyness JM, Noel TK, Cox C, King DA, Conwell Y, Caine ED: Screening for depression in elderly primary care patients. A comparison of the Center for Epidemiologic Studies-Depression Scale and the Geriatric Depression Scale. Arch Intern Med 157:449–454, 1997
Holcomb WLJr, Stone LS, Lustman PJ, Gavard JA, Mostello DJ: Screening for depression in pregnancy: Characteristics of the Beck Depression Inventory. Obstet Gynecol 88:1021–1025, 1996
Fass R, Mackel C, Sampliner RE: 24-hour pH monitoring in symptomatic patients without erosive esophagitis who did not respond to antireflux treatment. J Clin Gastroenterol 19:97–99, 1994
Fass R, Ofman JJ, Gralnek IM, et al: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 159:2161–2168, 1999
Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al: Omeprazole as a diagnostic tool in gastroesophageal reflux disease [see comments]. Am J Gastroenterol 92:1997–2000, 1997
The American College of Gastroenterology: The Richter Scale, 2000, www.acg.gi.org
Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JFJ. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274:474–477, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ofman, J.J., Shaw, M., Sadik, K. et al. Identifying Patients with Gastroesophageal Reflux Disease: Validation of a Practical Screening Tool. Dig Dis Sci 47, 1863–1869 (2002). https://doi.org/10.1023/A:1016421401519
Issue Date:
DOI: https://doi.org/10.1023/A:1016421401519